Denali Therapeutics Inc (NASDAQ: DNLI) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company does not generate product revenue from approved medicines; its income comes from collaboration agreements with partners including large pharmaceutical companies. Denali was founded and is headquartered in South San Francisco, California. Its pipeline targets diseases including Parkinson's disease, ALS, Alzheimer's disease, and lysosomal storage disorders, with a platform centered on its Transport Vehicle technology designed to cross the blood-brain barrier. As a pre-commercial biotechnology company, Denali funds operations primarily through collaboration and license payments rather than product sales.

Revenue model

Collaboration and license revenue from pharmaceutical partnership agreements. No approved product revenue as of the 10-K filed 2026-02-26.

Products and services

Clinical-stage drug pipeline targeting neurodegenerative diseases including Parkinson's disease, ALS, Alzheimer's disease, and lysosomal storage disorders. Proprietary Transport Vehicle (TV) platform for blood-brain barrier drug delivery.

Customers and end markets

Pharmaceutical company collaborators. End markets include patients with neurodegenerative diseases.

Value-chain role

Drug discovery and clinical development; upstream biopharmaceutical research organization reliant on partnership funding.

Geographic exposure

Headquartered in South San Francisco, California. Geographic revenue mix not determinable from available filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: ACADIA Pharmaceuticals Inc AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc Beam Therapeutics Inc Blueprint Medicines Corp ChemoCentryx, Inc. Mirati Therapeutics, Inc. PTC Therapeutics Inc Ultragenyx Pharmaceutical Inc